Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

Launched by LONDON HEALTH SCIENCES CENTRE RESEARCH INSTITUTE OR LAWSON RESEARCH INSTITUTE OF ST. JOSEPH'S · Apr 28, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how well a medication called dupilumab works for patients with chronic rhinosinusitis and nasal polyps, especially focusing on how it affects the sense of smell. Researchers will assess participants’ ability to smell using a test called the Sniffin' Sticks at three different visits over six months. They aim to see if dupilumab improves not just the ability to smell but also the overall nasal condition and quality of life for the patients involved.

To be eligible for this study, participants must be adults over 18 years old who have chronic rhinosinusitis with nasal polyps and have experienced a loss of smell. They should be considering treatment with dupilumab. However, individuals with smell loss due to other reasons, like certain cancers or injuries, or those who are pregnant, cannot participate. If you join the study, you can expect to have follow-up visits at the clinic to monitor your symptoms and how the treatment is working for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 18 years old
• • Chronic rhinosinusitis with Nasal Polyps
• • Olfactory loss
• • Clinical indication for treatment with Dupilumab
• Exclusion Criteria:
• Patients with olfactory loss from other causes such as:
• • Sinonasal malignancies
• • Trauma
• • Idiopathic olfactory loss
• • Use of cocaine
• • COVID-19 related olfactory loss
• • Pregnancy